PT1162995E - Enzimas para o tratamento da diabetes mellitus do tipo i - Google Patents

Enzimas para o tratamento da diabetes mellitus do tipo i

Info

Publication number
PT1162995E
PT1162995E PT00925114T PT00925114T PT1162995E PT 1162995 E PT1162995 E PT 1162995E PT 00925114 T PT00925114 T PT 00925114T PT 00925114 T PT00925114 T PT 00925114T PT 1162995 E PT1162995 E PT 1162995E
Authority
PT
Portugal
Prior art keywords
treatment
type
enzyme mixtures
pancreatin
diabetes mellitus
Prior art date
Application number
PT00925114T
Other languages
English (en)
Inventor
Friederike Henniges
Suntje Sander
Claus Steinborn
Martin Rudmann
Dieter Schwanitz
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of PT1162995E publication Critical patent/PT1162995E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Enzymes And Modification Thereof (AREA)
PT00925114T 1999-03-17 2000-03-15 Enzimas para o tratamento da diabetes mellitus do tipo i PT1162995E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19911778 1999-03-17

Publications (1)

Publication Number Publication Date
PT1162995E true PT1162995E (pt) 2003-08-29

Family

ID=7901217

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00925114T PT1162995E (pt) 1999-03-17 2000-03-15 Enzimas para o tratamento da diabetes mellitus do tipo i

Country Status (23)

Country Link
US (1) US7122357B2 (pt)
EP (1) EP1162995B1 (pt)
JP (1) JP4938174B2 (pt)
CN (1) CN1221284C (pt)
AT (1) ATE242003T1 (pt)
AU (1) AU773930B2 (pt)
BR (1) BR0009012A (pt)
CA (1) CA2367355C (pt)
CZ (1) CZ20013345A3 (pt)
DE (2) DE10012095A1 (pt)
DK (1) DK1162995T3 (pt)
ES (1) ES2194720T3 (pt)
HK (1) HK1044477B (pt)
HU (1) HUP0200556A3 (pt)
NO (1) NO20014507D0 (pt)
NZ (1) NZ514826A (pt)
PL (1) PL199180B1 (pt)
PT (1) PT1162995E (pt)
RU (1) RU2268065C2 (pt)
SK (1) SK284677B6 (pt)
TR (1) TR200102784T2 (pt)
WO (1) WO2000054799A2 (pt)
ZA (1) ZA200107110B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7020384B1 (en) 1999-08-12 2006-03-28 Lg Electronics Inc. Method for creating and recording transport time information for data recorded on a disk
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8100844B2 (en) * 2002-04-25 2012-01-24 Ultraflex Systems, Inc. Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint
US7519274B2 (en) 2003-12-08 2009-04-14 Divx, Inc. File format for multiple track digital data
BRPI0509148B8 (pt) 2004-03-22 2021-05-25 Abbott Products Gmbh composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina contendo tensoativos, seus usos e respectivos processos de fabricação
DK1755656T3 (da) * 2004-05-24 2010-10-04 Novozymes As Enzymer til farmaceutisk anvendelse
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
AU2006261442A1 (en) * 2005-06-24 2006-12-28 Novozymes A/S Lipases for pharmaceutical use
MX2007015474A (es) * 2005-06-24 2008-04-22 Novozymes As Proteasas para uso farmaceutico.
JP2008546396A (ja) * 2005-06-24 2008-12-25 ノボザイムス アクティーゼルスカブ 薬学的に使用するためのアミラーゼ
JP5140586B2 (ja) 2005-07-29 2013-02-06 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 滅菌パンクレアチン粉末の製法
NZ565959A (en) * 2005-08-15 2011-10-28 Solvay Pharm Gmbh Pancreatin micropellet cores suitable for enteric coating
AU2006281415B2 (en) * 2005-08-15 2012-01-19 Abbott Laboratories Gmbh Pancreatin micropellet cores suitable for enteric coating
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
NZ565960A (en) 2005-08-15 2012-03-30 Solvay Pharm Gmbh Controlled release pharmaceutical compositions for acid labile drugs
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
WO2007053619A2 (en) * 2005-11-01 2007-05-10 Bio-Cat, Inc. A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
CN105112386A (zh) 2006-12-21 2015-12-02 诺维信公司 用于药物用途的脂肪酶变体
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
WO2009071550A1 (en) 2007-12-04 2009-06-11 Novozymes A/S Protease variants for pharmaceutical use
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
GB2465814B (en) * 2008-06-19 2011-10-26 Tarig Sayed Mustafa Arbab Method,composition and device for the treatment of enzymes and saccharides disorders
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
ES2732453T3 (es) 2008-07-01 2019-11-22 Curemark Llc Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
GB2480772B (en) 2009-01-06 2013-10-16 Curelon Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus
EP2373693A4 (en) 2009-01-06 2012-04-25 Curelon Llc COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF ORAL INFECTIONS BY E. COLI
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
CN102946872A (zh) * 2010-05-03 2013-02-27 阿普塔利斯制药有限公司 包含含有胰酶的消化酶混合物的微丸组合物
WO2012145651A2 (en) 2011-04-21 2012-10-26 Curemark, Llc Compounds for the treatment of neuropsychiatric disorders
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
US20130273026A1 (en) * 2012-04-12 2013-10-17 Integrative Enzymatics, Inc. Composition and method for modulating inflammatory molecules with amylase
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
WO2019059158A1 (ja) * 2017-09-19 2019-03-28 学校法人明治大学 特定の機能細胞を欠損する臓器を発達させる方法
CN109142728A (zh) * 2018-09-04 2019-01-04 深圳市鸿美诊断技术有限公司 一种定量测定粪便中胰弹性蛋白酶1的试剂盒及其应用
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3803305A (en) * 1962-12-28 1974-04-09 Rolland A Lab Process for obtaining extracts from pancreas
DE2512746C3 (de) 1975-03-22 1980-04-24 Kali-Chemie Pharma Gmbh, 3000 Hannover Verfahren zur Herstellung von keimarmem, faserfreiem Pankreatin
SU908352A1 (ru) * 1980-02-11 1982-02-28 Винницкий Областной Госпиталь Для Инвалидов Отечественной Войны Способ лечени гнойных ран
DE4203315A1 (de) 1991-02-14 1992-08-20 Kali Chemie Pharma Gmbh Verfahren zur gewinnung von pankreatin
US5614224A (en) * 1995-04-20 1997-03-25 Womack; Rick W. Nutritional supplement for diabetics

Also Published As

Publication number Publication date
DE50002450D1 (de) 2003-07-10
HK1044477B (zh) 2006-02-03
PL350627A1 (en) 2003-01-27
SK284677B6 (sk) 2005-09-08
US20020061302A1 (en) 2002-05-23
AU4395000A (en) 2000-10-04
CA2367355C (en) 2012-06-05
HUP0200556A2 (en) 2002-06-29
EP1162995A2 (de) 2001-12-19
NZ514826A (en) 2003-08-29
SK12852001A3 (sk) 2002-02-05
ES2194720T3 (es) 2003-12-01
NO20014507L (no) 2001-09-17
PL199180B1 (pl) 2008-08-29
DE10012095A1 (de) 2000-09-21
EP1162995B1 (de) 2003-06-04
CA2367355A1 (en) 2000-09-21
HUP0200556A3 (en) 2006-06-28
TR200102784T2 (tr) 2002-04-22
ZA200107110B (en) 2002-10-30
CZ20013345A3 (cs) 2002-01-16
ATE242003T1 (de) 2003-06-15
AU773930B2 (en) 2004-06-10
JP2002539173A (ja) 2002-11-19
RU2268065C2 (ru) 2006-01-20
US7122357B2 (en) 2006-10-17
HK1044477A1 (en) 2002-10-25
CN1221284C (zh) 2005-10-05
BR0009012A (pt) 2001-12-26
WO2000054799A3 (de) 2001-04-26
JP4938174B2 (ja) 2012-05-23
DK1162995T3 (da) 2003-06-23
WO2000054799A2 (de) 2000-09-21
CN1343126A (zh) 2002-04-03
NO20014507D0 (no) 2001-09-17

Similar Documents

Publication Publication Date Title
PT1162995E (pt) Enzimas para o tratamento da diabetes mellitus do tipo i
RU2001126526A (ru) Лекарственное средство, предназначенное для лечения диабета
MXPA06001173A (es) Metodo analitico para la pancreatina y composiciones comparables.
FI925787A (fi) Proteolytiska enzymers sackarinderivatinhibitorer
HUP0500560A2 (hu) Mikróbás enzimek új keverékei
BR0009167A (pt) Inibidores de enzima impdh
MY129998A (en) Saccharin derivative proteolytic enzyme inhibitors
MXPA02012272A (es) Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv.
JP2002539173A5 (pt)
HK1060045A1 (en) Formulations comprising ibuprofen and diphenhydramine and the use thereof for the treatment of sleepdisturbances
BRPI0510817A (pt) protease, uso de uma protease, composição farmacêutica, e, método para o tratamento de uma doença
RU2008102738A (ru) Протеазы для фармацевтического применения
CA2549185A1 (en) Peptide inhibiting angiotensin converting enzyme
TR200101980T2 (tr) Arilalkanoil türevleri, bunların preparasyon işlemleri
TW200507861A (en) Antiobesity agent using hen-egg antibody against digestive enzyme
ZA200209714B (en) Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV.
YU31902A (sh) Polipeptidna kompozicija
TW200512193A (en) Pyridinyl carbamates